Dr. Dubinsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
17 E 102nd St
New York, NY 10029Phone+1 212-241-5415Fax+1 212-241-1597
Summary
- Dr. Marla Dubinsky is a pediatric gastroenterologist in New York, NY and is affiliated with multiple hospitals in the area, including Mount Sinai Hospital, Mount Sinai West, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, and Mount Sinai West. She received her medical degree from Other and has been in practice 24 years. She specializes in pediatric inflammatory bowel disease gastroenterology and is experienced in inflammatory bowel disease.
Education & Training
- Queen's University at KingstonClass of 1993
Certifications & Licensure
- CA State Medical License 2001 - Present
- FL State Medical License 2020 - Present
- NY State Medical License 2014 - 2025
- American Board of Pediatrics Pediatric Gastroenterology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children Start of enrollment: 2007 Jun 01
- Individualized Infiximab Dosing-Proof of Concept Study Start of enrollment: 2013 Nov 01
- The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness Start of enrollment: 2015 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 578 citationsDeep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease.Manuel A. Rivas, Mélissa Beaudoin, Agnes Gardet, Christine Stevens, Yashoda Sharma
Nature Genetics. 2011-11-01 - 2725 citationsHost-microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseLuke Jostins, Stephan Ripke, Rinse K. Weersma, Richard H. Duerr, Dermot P.B. McGovern
Nature. 2012-11-01 - 126 citationsRisankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.Geert D'Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel
Lancet. 2022-05-28
Journal Articles
- Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel DiseasesRyan Ungaro, Daniel J Stein, Andres J Yarur, Amir Patel, Marla Dubinsky, Digestive Diseases and Sciences
- Genetic and Transcriptomic Variation Linked to Neutrophil Granulocyte–Macrophage Colony-Stimulating Factor Signaling in Pediatric Crohn’s DiseaseLee A Denson, Bruce J Aronow, Barbara S Kirschner, Joshua D Noe, Melvin B Heyman, Ramnik J Xavier, Robert N Baldassano, Jeffrey S Hyams, Subra Kugathasan, Wallace V Cr..., Inflammatory Bowel Diseases
- Utility of Video Capsule Endoscopy for Longitudinal Monitoring of Crohn’s Disease Activity in the Small Bowel: A Prospective StudyGil Y Melmed, Marla C Dubinsky, David T Rubin, Shabana F Pasha, Atsushi Sakuraba, Felix Tiongco, Ira Shafran, Jonathan A Leighton, Gastrointestinal Endoscopy
- Join now to see all
Press Mentions
- Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative ColitisMay 9th, 2023
- Prometheus Launches New Indication for PredictrPK® IFX, a Precision-Guided Dosing Test for IBDMarch 2nd, 2023
- Subcutaneous Skyrizi Beneficial in Delayed, Non-Responders to IV Induction Therapy for CDNovember 2nd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: